KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Average (2020 - 2025)

Historic Equity Average for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $9.6 billion.

  • Royalty Pharma's Equity Average fell 443.01% to $9.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year decrease of 443.01%. This contributed to the annual value of $10.2 billion for FY2024, which is 416.63% up from last year.
  • Latest data reveals that Royalty Pharma reported Equity Average of $9.6 billion as of Q3 2025, which was down 443.01% from $9.6 billion recorded in Q2 2025.
  • Royalty Pharma's 5-year Equity Average high stood at $10.4 billion for Q3 2022, and its period low was $9.6 billion during Q3 2025.
  • In the last 5 years, Royalty Pharma's Equity Average had a median value of $10.0 billion in 2024 and averaged $10.0 billion.
  • Per our database at Business Quant, Royalty Pharma's Equity Average surged by 4832.12% in 2021 and then plummeted by 684.67% in 2023.
  • Over the past 5 years, Royalty Pharma's Equity Average (Quarter) stood at $10.3 billion in 2021, then decreased by 3.36% to $10.0 billion in 2022, then decreased by 1.37% to $9.8 billion in 2023, then rose by 4.74% to $10.3 billion in 2024, then decreased by 7.17% to $9.6 billion in 2025.
  • Its Equity Average was $9.6 billion in Q3 2025, compared to $9.6 billion in Q2 2025 and $10.1 billion in Q1 2025.